Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $20.59 USD
Change Today -0.17 / -0.82%
Volume 1.2M
As of 8:10 PM 05/26/15 All times are local (Market data is delayed by at least 15 minutes).

depomed inc (DEPO) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/27/15 - $28.16
52 Week Low
08/1/14 - $9.85
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for DEPOMED INC (DEPO)

depomed inc (DEPO) Related Businessweek News

No Related Businessweek News Found

depomed inc (DEPO) Details

Depomed, Inc., a specialty pharmaceutical company, develops products for pain and other central nervous system conditions in the United States. It offers Gralise (gabapentin), an once-daily product for the management of postherpetic neuralgia; CAMBIA (diclofenac potassium for oral solution), a non-steroidal anti-inflammatory drug indicated for acute treatment of migraine attacks in adults; Zipsor (diclofenac potassium) liquid filled capsule, a non-steroidal anti-inflammatory drug for the treatment of mild to moderate acute pain in adults; and Lazanda (fentanyl) nasal spray, an intranasal fentanyl drug used to manage breakthrough pain in adults. The company is involved in the clinical development of IW-3718 refractory gastroesophageal reflux disease program using Acuform drug delivery technology. Depomed, Inc. sells its Gralise products to wholesalers and retail pharmacies. The company also has a portfolio of royalty and milestone producing license agreements based on its proprietary Acuform gastroretentive drug delivery technology with Mallinckrodt Inc.; Ironwood Pharmaceuticals, Inc.; and Janssen Pharmaceuticals, Inc. The company was founded in 1995 and is headquartered in Newark, California.

324 Employees
Last Reported Date: 02/26/15
Founded in 1995

depomed inc (DEPO) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $620.1K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $374.8K
Senior Vice President and General Counsel
Total Annual Compensation: $396.6K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $211.9K
Senior Vice President of Business Development
Total Annual Compensation: $316.7K
Compensation as of Fiscal Year 2014.

depomed inc (DEPO) Key Developments

DepoMed Inc. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-14-2015 10:00 AM

DepoMed Inc. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-14-2015 10:00 AM. Venue: Encore at the Wynn, 3131 S Las Vegas Blvd, Las Vegas, Nevada, United States. Speakers: August J. Moretti, Chief Financial Officer, Principal Accounting Officer and Senior Vice President.

DepoMed Inc. Approves Amendment to its Amended and Restated Articles of Incorporation

Depomed Inc. announced at the AGM held on May 12, 2015, the shareholders approved an amendment to the company’s amended and restated articles of incorporation to increase the number of authorized shares of common stock by 100,000,000 shares.

DepoMed Inc. Reports Un-Audited Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Provides Earnings Guidance for the Year 2015

DepoMed Inc. reported un-audited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported total revenues of $32.2 million compared to $76.5 million, loss from operations of $9.8 million compared to income from operations of $35.7 million and net loss of $11.6 million or $0.20 per diluted share compared to net income of $17.9 million or $0.30 per diluted share for the last year. Non-GAAP adjusted loss of $8.0 million or $0.13 per share compared to $0.8 million or $0.01 per share in last year. For the year, the company expected total product sales of $310 to $335 million, intangible asset amortization of $85 to $90 million, non-GAAP adjusted earnings of $16 to $28 million and adjusted EBITDA of $85 to $100 million. The company expected total revenues to be approximately the same, not anticipating any milestone revenue in 2015, and only a modest amount of royalty revenue.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DEPO:US $20.59 USD -0.17

DEPO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Acorda Therapeutics Inc $31.61 USD -0.40
Biocon Ltd 448.10 INR -0.65
Emergent Biosolutions Inc $30.43 USD -0.37
Insys Therapeutics Inc $59.72 USD +0.41
Nektar Therapeutics $11.53 USD -0.34
View Industry Companies

Industry Analysis


Industry Average

Valuation DEPO Industry Range
Price/Earnings 13.5x
Price/Sales 3.6x
Price/Book 3.5x
Price/Cash Flow 11.1x
TEV/Sales 2.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DEPOMED INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at